Kazuya Shimura

List of Publications by Year
in descending order

24 papers	1,013 citations	567281 15 h-index	610901 24 g-index
24 all docs	24 docs citations	24 times ranked	1332 citing authors

#	Article	IF	Citations
1	Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	23
2	Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Cell Reports, 2021, 36, 109385.	6.4	23
3	Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors. Biochemistry and Biophysics Reports, 2019, 20, 100687.	1.3	3
4	Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1269-E1278.	7.1	135
5	Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors. Retrovirology, 2016, 13, 70.	2.0	10
6	Investigations of possible prodrug structures for 2-(2-mercaptophenyl)tetrahydropyrimidines: reductive conversion from anti-HIV agents with pyrimidobenzothiazine and isothiazolopyrimidine scaffolds. Organic and Biomolecular Chemistry, 2015, 13, 4706-4713.	2.8	14
7	Identification of anti-HIV agents with a novel benzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold. Bioorganic and Medicinal Chemistry, 2015, 23, 1447-1452.	3.0	19
8	Impact of HIV-1 infection pathways on susceptibility to antiviral drugs and on virus spread. Virology, 2015, 484, 364-376.	2.4	9
9	Structureâ€“activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4557-4561.	2.2	22
10	Design and synthesis of biotin- or alkyne-conjugated photoaffinity probes for studying the target molecules of PD 404182. Bioorganic and Medicinal Chemistry, 2013, 21, 2079-2087.	3.0	14
11	Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. International Journal of Biochemistry and Cell Biology, 2013, 45, 908-915.	2.8	6
12	HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 4035-4038.	3.2	6
13	ComprehensiveIn VitroAnalysis of Simian Retrovirus Type 4 Susceptibility to Antiretroviral Agents. Journal of Virology, 2013, 87, 4322-4329.	3.4	6
14	CXCR4 Stimulates Macropinocytosis: Implications for Cellular Uptake of Arginine-Rich Cell-Penetrating Peptides and HIV. Chemistry and Biology, 2012, 19, 1437-1446.	6.0	103
15	Structureâ€“activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents. Bioorganic and Medicinal Chemistry, 2012, 20, 6434-6441.	3.0	25
16	Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles. Organic and Biomolecular Chemistry, 2012, 10, 6792.	2.8	24
17	Potent CXCR4 Antagonists Containing Amidine Type Peptide Bond Isosteres. ACS Medicinal Chemistry Letters, 2011, 2, 477-480.	2.8	33
18	Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. Antiviral Research, 2010, 87, 179-186.	4.1	17

#	Article	IF	Citations
19	Resistance Profiles of Novel Electrostatically Constrained HIV-1 Fusion Inhibitors. Journal of Biological Chemistry, 2010, 285, 39471-39480.	3.4	37
20	Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20*. Journal of Biological Chemistry, 2009, 284, 4914-4920.	3.4	41
21	Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. Antiviral Research, 2009, 82, 67-72.	4.1	25
22	Elvitegravir: A New HIV Integrase Inhibitor. Antiviral Chemistry and Chemotherapy, 2009, 20, 79-85.	0.6	86
23	Elvitegravir: an emerging HIV integrase inhibitor. Future HIV Therapy, 2008, 2, 411-418.	0.4	2
24	Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). Journal of Virology, 2008, 82, 764-774.	3.4	330